Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) tinted gains of +5.16% (+0.28 points) to US$5.71. The volume of 0.52 Million shares climbed down over an trading activity of 86.65 Million shares. EPS ratio determined by looking at last 12 month figures is -2.06. Over the same time span, the stock marked US$7.45 as its best level and the lowest price reached was US$4.34. The corporation has a market cap of US$229.48 Million.
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 27.6 percent. The return on equity ratio or ROE stands at -103.6 percent while most common profitability ratio return on investment (ROI) was -97.3 percent. The company’s institutional ownership is monitored at 53.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 99.6 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Planet Fitness, Inc. (NYSE:PLNT) is worth US$4.58 Billion and has recently risen 5.11% to US$47.5. The latest exchange of 1.08 Million shares is above its average trading activity of 1 Million shares. The day began at US$46 but the price moved to US$45.87 at one point during the trading and finally capitulating to a session high of US$47.58. The stock tapped a 52-week high of US$46.81 while the mean 12-month price target for the shares is US$41.33.
Currently, the stock carries a price to earnings ratio of 10.82, a price to book ratio of 0, and a price to sales ratio of 9.95. For the past 5 years, the company’s revenue has grown 21.9%, while the company’s earnings per share has grown 80%. With an institutional ownership near 0%, it carries an earnings per share ratio of 4.39.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 6 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 6 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.71.